December 1, 2025
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025”)
Injuries are part of living. Scrapes, fractures, and scar healing remind us that the body can repair itself. However, some wounds go deeper, beyond what nature and conventional treatments can do. For instance, when you have an injury in complex or protected areas of the body like the brain and
Design Targeted Cell & Gene Therapies. Master Cell Therapy Manufacturing. Accelerate Patient Access. R&D • Manufacturing • Analytics • Clinical • Regulatory • Investment
NEW YORK, Nov. 18, 2025 /PRNewswire/ — The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the inaugural 2025 Prix Galien Bridges Awards nominees for “Best Bridge-Builder Institution,” “Best Biomedical Product,” “Best Medical Technology/AI Advances in Human Health,” “Best Product for Rare/Orphan Diseases,” and “Best Public
TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its press release dated October 8, 2025 (the “October 8 Release”), the Company has received gross proceeds of over C$3.18M through accelerated warrant exercises.
TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program. The federally-supported program, launched
As exosomes have emerged as a next-generation therapeutic platform for multiple diseases, leaders in the RNA community are now focusing on these nanoparticles as the ultimate drug delivery system for a wide range of indications from oncology to dermatology. NurExone has taken a unique approach and is using exosome therapies